160 related articles for article (PubMed ID: 24167945)
1. [Homocysteine and its role in pathogenesis of Parkinson's disease and other neurodegenerative disorders].
Szadejko K; Szabat K; Ludwichowska A; Sławek J
Przegl Lek; 2013; 70(7):443-7. PubMed ID: 24167945
[TBL] [Abstract][Full Text] [Related]
2. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
Lamberti P; Zoccolella S; Iliceto G; Armenise E; Fraddosio A; de Mari M; Livrea P
Mov Disord; 2005 Jan; 20(1):69-72. PubMed ID: 15390046
[TBL] [Abstract][Full Text] [Related]
3. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients.
Valkovic P; Benetin J; Blazícek P; Valkovicová L; Gmitterová K; Kukumberg P
Parkinsonism Relat Disord; 2005 Jun; 11(4):253-6. PubMed ID: 15878587
[TBL] [Abstract][Full Text] [Related]
4. Serum homocysteine and physical exercise in patients with Parkinson's disease.
Nascimento CM; Stella F; Garlipp CR; Santos RF; Gobbi S; Gobbi LT
Psychogeriatrics; 2011 Jun; 11(2):105-12. PubMed ID: 21707858
[TBL] [Abstract][Full Text] [Related]
5. Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?
Kocer B; Guven H; Comoglu SS
Biomed Res Int; 2016; 2016():7563705. PubMed ID: 27493964
[TBL] [Abstract][Full Text] [Related]
6. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
[TBL] [Abstract][Full Text] [Related]
7. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.
Białecka M; Kurzawski M; Roszmann A; Robowski P; Sitek EJ; Honczarenko K; Gorzkowska A; Budrewicz S; Mak M; Jarosz M; Gołąb-Janowska M; Koziorowska-Gawron E; Droździk M; Sławek J
Pharmacogenet Genomics; 2012 Oct; 22(10):716-24. PubMed ID: 22890010
[TBL] [Abstract][Full Text] [Related]
8. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital.
Ojo OO; Oladipo OO; Ojini FI; Sanya EO; Danesi MA; Okubadejo NU
West Afr J Med; 2011; 30(5):319-24. PubMed ID: 22752818
[TBL] [Abstract][Full Text] [Related]
9. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
Zoccolella S; dell'Aquila C; Abruzzese G; Antonini A; Bonuccelli U; Canesi M; Cristina S; Marchese R; Pacchetti C; Zagaglia R; Logroscino G; Defazio G; Lamberti P; Livrea P
Mov Disord; 2009 May; 24(7):1028-33. PubMed ID: 19353704
[TBL] [Abstract][Full Text] [Related]
10. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration.
Lamberti P; Zoccolella S; Armenise E; Lamberti SV; Fraddosio A; de Mari M; Iliceto G; Livrea P
Eur J Neurol; 2005 May; 12(5):365-8. PubMed ID: 15804266
[TBL] [Abstract][Full Text] [Related]
11. The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status.
Zesiewicz TA; Wecker L; Sullivan KL; Merlin LR; Hauser RA
Clin Neuropharmacol; 2006; 29(3):106-11. PubMed ID: 16772808
[TBL] [Abstract][Full Text] [Related]
12. Effects of vitamin B12, folate, and entacapone on homocysteine levels in levodopa-treated Parkinson's disease patients: A randomized controlled study.
Anamnart C; Kitjarak R
J Clin Neurosci; 2021 Jun; 88():226-231. PubMed ID: 33992189
[TBL] [Abstract][Full Text] [Related]
13. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Di Rocco A; Werner P
Neurology; 2004 Feb; 62(4):676; author reply 676-7. PubMed ID: 14981202
[No Abstract] [Full Text] [Related]
14. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study.
Postuma RB; Espay AJ; Zadikoff C; Suchowersky O; Martin WR; Lafontaine AL; Ranawaya R; Camicioli R; Lang AE
Neurology; 2006 Jun; 66(12):1941-3. PubMed ID: 16801668
[TBL] [Abstract][Full Text] [Related]
15. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status.
Schroecksnadel K; Leblhuber F; Fuchs D
Neurology; 2004 Feb; 62(4):676; author reply 676-7. PubMed ID: 14994447
[No Abstract] [Full Text] [Related]
16. Genetic and environmental factors for hyperhomocysteinaemia and its clinical implications in Parkinson's disease.
Białecka M; Robowski P; Honczarenko K; Roszmann A; Sławek J
Neurol Neurochir Pol; 2009; 43(3):272-85. PubMed ID: 19618311
[TBL] [Abstract][Full Text] [Related]
17. Hyperhomocysteinemia due to levodopa treatment as a risk factor for osteoporosis in patients with Parkinson's disease.
Lee SH; Kim MJ; Kim BJ; Kim SR; Chun S; Kim HK; Ryu JS; Kim GS; Lee MC; Chung SJ; Koh JM
Calcif Tissue Int; 2010 Feb; 86(2):132-41. PubMed ID: 20049422
[TBL] [Abstract][Full Text] [Related]
18. Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review.
Zoccolella S; Iliceto G; deMari M; Livrea P; Lamberti P
Clin Chem Lab Med; 2007; 45(12):1607-13. PubMed ID: 17963454
[TBL] [Abstract][Full Text] [Related]
19. Hyperhomocysteinemia in movement disorders: Current evidence and hypotheses.
Zoccolella S; Martino D; Defazio G; Lamberti P; Livrea P
Curr Vasc Pharmacol; 2006 Jul; 4(3):237-43. PubMed ID: 16842141
[TBL] [Abstract][Full Text] [Related]
20. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease.
Rogers JD; Sanchez-Saffon A; Frol AB; Diaz-Arrastia R
Arch Neurol; 2003 Jan; 60(1):59-64. PubMed ID: 12533089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
